NCT04483206View on ClinicalTrials.gov

Personalized Autologous Transplant for Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Multiple Myeloma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo ASCT

DRUG

Melphalan

Given IV

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

60607

NOT_YET_RECRUITING

University Illinois Chicago, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Gateway for Cancer Research

OTHER

lead

Emory University

OTHER

NCT04483206 - Personalized Autologous Transplant for Multiple Myeloma | Biotech Hunter | Biotech Hunter